for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Codexis, Inc.

CDXS.OQ

Latest Trade

13.75USD

Change

0.00(0.00%)

Volume

75,827

Today's Range

13.32

 - 

13.81

52 Week Range

12.69

 - 

23.01

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Codexis Reports Q2 2019 Results

Aug 6 (Reuters) - Codexis Inc <CDXS.O>::CODEXIS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS.Q2 NON-GAAP LOSS PER SHARE $0.08.Q2 LOSS PER SHARE $0.12.Q2 REVENUE $12.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $14.2 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $-0.10 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $69 MILLION TO $72 MILLION.AFFIRMING ITS FINANCIAL GUIDANCE FOR 2019.FY2019 REVENUE VIEW $70.5 MILLION -- REFINITIV IBES DATA.

Codexis Inc - Announces Signing Of A Codeevolver Platform Agreement With Novartis

May 15 (Reuters) - Codexis Inc <CDXS.O>::CODEXIS INC - ANNOUNCES SIGNING OF A CODEEVOLVER PLATFORM AGREEMENT WITH NOVARTIS.CODEXIS - UNDER TERMS, NOVARTIS WILL PAY CO UPFRONT PAYMENT, MILESTONE PAYMENTS UPON SATISFACTORY COMPLETION OF TECHNOLOGY TRANSFER.CODEXIS - WILL BE ELIGIBLE TO GET PAYMENTS FOR ACTIVE PHARMACEUTICAL INGREDIENTS MADE WITH ENZYMES DEVELOPED BY NOVARTIS USING CODEEVOLVER TECHNOLOGY.CODEXIS INC - RECEIVES CERTAIN RIGHTS FOR FUTURE PURCHASES OF ENZYMES DEVELOPED & SOURCED BY NOVARTIS USING CODEEVOLVER TECHNOLOGY.

Codexis Entered Into Platform Technology Transfer And License Agreement With Novartis

May 6 (Reuters) - Codexis Inc <CDXS.O>::CODEXIS INC - ON MAY 2, 2019 ENTERED INTO PLATFORM TECHNOLOGY TRANSFER AND LICENSE AGREEMENT WITH NOVARTIS PHARMA AG - SEC FILING.CODEXIS -UNDER AGREEMENT,GRANTED TO NOVARTIS WORLDWIDE LICENSE TO USE CO'S CODEEVOLVER PLATFORM TECHNOLOGY TO RESEARCH, DEVELOP,MANUFACTURE NOVEL ENZYMES.CODEXIS INC -UNDER AGREEMENT, NOVARTIS WILL PAY CODEXIS UP TO $14 MILLION OVER APPROXIMATELY NEXT 22 MONTHS.CODEXIS - IF NOVARTIS EXERCISES TERMINATION RIGHT BEFORE MAKING FIRST TECHNOLOGY TRANSFER MILESTONE PAYMENT, NOVARTIS TO MAKE 1-TIME TERMINATION PAYMENT OF $9 MILLION.CODEXIS - IF NOVARTIS EXERCISES TERMINATION RIGHT BEFORE MAKING SECOND TECHNOLOGY TRANSFER MILESTONE PAYMENT, NOVARTIS TO MAKE 1-TIME TERMINATION PAYMENT OF $5 MILLION.

Codexis Reports Q1 Non-GAAP Loss Per Share $0.05

May 6 (Reuters) - Codexis Inc <CDXS.O>::CODEXIS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS.Q1 NON-GAAP LOSS PER SHARE $0.05.Q1 LOSS PER SHARE $0.09.Q1 REVENUE $15.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $14.6 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $-0.10 -- REFINITIV IBES DATA.SEES FY 2019 REVENUE $69 MILLION TO $72 MILLION.FY2019 REVENUE VIEW $70.9 MILLION -- REFINITIV IBES DATA.

Codexis Signs Multi-Year Enzyme Supply And Licensing Agreement

April 30 (Reuters) - Codexis Inc <CDXS.O>::CODEXIS SIGNS MULTI-YEAR ENZYME SUPPLY AND LICENSING AGREEMENT WITH TATE & LYLE FOR THE MANUFACTURE OF TASTEVA® M STEVIA SWEETENER.CODEXIS - MULTI-YEAR DEAL WITH TATE & LYLE FOR SUPPLY, LICENSING OF NOVEL CODEXIS PERFORMANCE ENZYMES USED IN MANUFACTURE OF TATE & LYLE'S TASTEVA.

Codexis Reports 2018 Fourth Quarter And Full Year Financial Results

Feb 26 (Reuters) - Codexis Inc <CDXS.O>::CODEXIS REPORTS 2018 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS.Q4 NON-GAAP EARNINGS PER SHARE $0.03.Q4 LOSS PER SHARE $0.01.Q4 REVENUE $16.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $16.7 MILLION.SEES FY 2019 REVENUE $69 MILLION TO $72 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $-0.03 -- REFINITIV IBES DATA.PRODUCT SALES ARE EXPECTED TO BE $26 MILLION TO $29 MILLION IN 2019.GROSS MARGIN ON PRODUCT SALES IS EXPECTED TO BE 48% TO 52% IN 2019.

Codexis Announces Enzyme Supply Agreement With Kyorin Pharmaceutical For Overactive Bladder Drug Sold In Japan

Feb 6 (Reuters) - Codexis Inc <CDXS.O>::CODEXIS ANNOUNCES ENZYME SUPPLY AGREEMENT WITH KYORIN PHARMACEUTICAL FOR OVERACTIVE BLADDER DRUG SOLD IN JAPAN.CODEXIS INC - ANNOUNCES A MULTI-YEAR, EXCLUSIVE SUPPLY AGREEMENT WITH KYORIN PHARMACEUTICAL CO., LTD..

Codexis Q3 Non-Gaap Earnings Per Share $0.00

Nov 8 (Reuters) - Codexis Inc <CDXS.O>::CODEXIS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $0.00.Q3 LOSS PER SHARE $0.04.Q3 REVENUE $16.9 MILLION VERSUS I/B/E/S VIEW $14.8 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.07 -- THOMSON REUTERS I/B/E/S.SEES FY 2018 REVENUE $60 MILLION TO $62 MILLION.FY2018 REVENUE VIEW $62.3 MILLION -- THOMSON REUTERS I/B/E/S.

Codexis Q2 Loss Per Share $0.07

Codexis Inc <CDXS.O>::CODEXIS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 NON-GAAP LOSS PER SHARE $0.02.Q2 LOSS PER SHARE $0.07.Q2 REVENUE $13.5 MILLION VERSUS I/B/E/S VIEW $11.6 MILLION.SEES FY 2018 REVENUE $60 MILLION TO $63 MILLION.Q2 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S.PHASE 1A CLINICAL TRIAL FOR CDX-6114 INITIATED.SEES FY PRODUCT REVENUE TO BE $25 MILLION TO $28 MILLION.

Codexis Reports Q1 Loss Per Share $0.10

May 10 (Reuters) - Codexis Inc <CDXS.O>::CODEXIS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.Q1 NON-GAAP LOSS PER SHARE $0.05.Q1 LOSS PER SHARE $0.10.Q1 REVENUE $14 MILLION VERSUS I/B/E/S VIEW $12.1 MILLION.SEES FY 2018 REVENUE $60 MILLION TO $63 MILLION.Q1 EARNINGS PER SHARE VIEW $-0.12 -- THOMSON REUTERS I/B/E/S.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up